Mizuho Securities analyst Salim Syed maintained a Buy rating on Neon Therapeutics Inc (NTGN) on June 15 and set a price target of $21. The company’s shares closed yesterday at $4.98, close to its 52-week low of $4.20.
According to TipRanks.com, Syed is a 1-star analyst with an average return of -3.3% and a 45.0% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Atara Biotherapeutics, and Wave Life Sciences.
Neon Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $20.25.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16.23 and a one-year low of $4.20. Currently, Neon Therapeutics Inc has an average volume of 149.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neon Therapeutics, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials.
